Close

Pfizer (PFE) Secures EC Marketing Authorization for Treatment of Rheumatoid Arthritis

March 27, 2017 5:43 AM EDT Send to a Friend
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login